Type of information: Private placement
Company: Oasmia Pharmaceutical (Sweden)
Amount: SEK 35.2 million
Funding type: private placement
- Oasmia Pharmaceutical intends to use the proceeds from the private placement to strengthen its working capital as well as finance its continuing operations. The board of directors has determined, given the phase the company is currently in, that this financing will give it time to finalize certain ongoing activities which the board of directors anticipates will be the basis to fulfil the company’s long term commercial strategy.
- • On September 7, 2018, Oasmia has completed a private placement of new convertible instruments in the amount SEK 35.2 million with an interest rate of 8 per cent per year directed to and placed with a limited group of investors and paid in cash. The convertible instrument issue is expected to provide the Company with SEK 35,200,000 before transaction related costs. Meanwhile, the Company informs that the Board of Directors of Oasmia has issued and allocated 8,064,516 new shares by virtue of utilisation of warrants of series 2018/2019. The Private Placement has enabled Oasmia to place 32 new convertible instruments with a limited group of investors at a nominal value of SEK 1,100,000 per convertible instrument through an accelerated book building procedure.
Therapeutic area: Cancer - Oncology